clinical trial · NCT07459660
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Psychosis Associated With Alzheimer's DiseaseML-007C-MA
brief summary
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).
started
Mar 25, 2026
primary completion
Mar 1, 2029
completion
Mar 1, 2029
last updated
Apr 14, 2026
official title
An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML007C-MA in Adult Participants With Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol